ArticleFrontiers in immunology2026
Radiomics and blood biomarkers for predicting efficacy of sintilimab plus lenvatinib in advanced hepatocellular carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint inhibitor-based combination therapy has emerged as an important treatment option for advanced hepatocellular carcinoma (HCC), yet therapeutic response remains highly heterogeneous. Biomarkers that jointly reflect tumor-intrinsic heterogeneity and host immune status are needed to improve response stratification and better understand variability in immunotherapy outcomes. Methods: We evaluated the predictive value of Computed Tomography (CT) -derived radiomic heterogeneity and systemic inflammatory biomarkers in patients with advanced HCC treated with sintilimab plus lenvatinib. A total of 62 patients were included and divided into a training cohort (n = 36) and an independent real-world validation cohort (n = 26). Radiomic features were extracted from multiphase contrast-enhanced CT and summarized as a radiomics score. Hematological indices reflecting systemic immune-inflammatory status were assessed in parallel. An integrated model combining imaging-derived heterogeneity and immune-inflammatory markers was constructed for response stratification. Results: The radiomics score discriminated responders from non-responders with area under the curve (AUC) values of 0.840 in the training cohort and 0.759 in the validation cohort. Among systemic biomarkers, the systemic immune-inflammation index (SII) was independently associated with treatment response. The integrated model combining radiomic heterogeneity and SII demonstrated improved discriminatory performance (AUC 0.938 and 0.819 in training and validation cohorts, respectively). Stratification based on the combined model was associated with differences in event-free survival, supporting the biological relevance of multimodal immune-tumor characterization. Conclusions: Integrating imaging-derived tumor heterogeneity with systemic immune-inflammatory status may provide a biologically informed and non-invasive strategy for exploratory response stratification in advanced HCC undergoing immune checkpoint inhibitor-based therapy. Larger multicenter studies incorporating prospective validation and immune profiling are warranted to confirm clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.